{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:46:11Z","timestamp":1790145971531,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.diabres.2025.112197","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T19:07:09Z","timestamp":1745262429000},"page":"112197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients"],"prefix":"10.1016","volume":"224","author":[{"given":"Ting-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1723-828X","authenticated-orcid":false,"given":"Yu-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng-Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2025.112197_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101580","article-title":"Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach","volume":"51","author":"Nandi","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2025.112197_b0010","unstructured":"Organization WH. Global status report on the public health response to dementia; 2021."},{"issue":"6","key":"10.1016\/j.diabres.2025.112197_b0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1001\/jamaneurol.2023.0697","article-title":"Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes","volume":"80","author":"Moran","year":"2023","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112197_b0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nrendo.2010.228","article-title":"Cognitive function, dementia and type 2 diabetes mellitus in the elderly","volume":"7","author":"Strachan","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112197_b0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/bmb\/ldn042","article-title":"The relationship between type 2 diabetes and dementia","volume":"88","author":"Strachan","year":"2008","journal-title":"Br Med Bull"},{"key":"10.1016\/j.diabres.2025.112197_b0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2147\/CIA.S74042","article-title":"Link between type 2 diabetes and Alzheimer\u2019s disease: from epidemiology to mechanism and treatment","author":"Li","year":"2015","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.diabres.2025.112197_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.777861","article-title":"Sodium-glucose cotransporter 2 inhibitors mechanisms of action: a review","volume":"8","author":"Fonseca-Correa","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112197_b0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: A novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Trans Neurodegener"},{"key":"10.1016\/j.diabres.2025.112197_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabres.2025.112197_b0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-079475","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.diabres.2025.112197_b0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium\u2013glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2025.112197_b0060","unstructured":"TriNetX https:\/\/trinetx.com. Accessed January 2, 2025."},{"issue":"5","key":"10.1016\/j.diabres.2025.112197_b0065","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S2215-0366(21)00084-5","article-title":"6-month neurological and psychiatric outcomes in 236\u2009379 survivors of COVID-19: a retrospective cohort study using electronic health records","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.diabres.2025.112197_b0070","article-title":"Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: A retrospective cohort study from the TriNetX US collaborative networks","volume":"53","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabres.2025.112197_b0075","article-title":"The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and seizure following COVID-19: A retrospective cohort study including 91,528 patients","author":"Liu","year":"2023","journal-title":"J Infect"},{"issue":"15","key":"10.1016\/j.diabres.2025.112197_b0080","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The Propensity Score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.diabres.2025.112197_b0085","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1111\/dom.15918","article-title":"Association of sodium\u2010glucose cotransporter 2 inhibitors with risk of incident dementia and all\u2010cause mortality in older patients with type 2 diabetes: a retrospective cohort study using the TriNetX US collaborative networks","volume":"26","author":"Pai","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112197_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2024-004541","article-title":"Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study","volume":"13","author":"Abdullah","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"10.1016\/j.diabres.2025.112197_b0095","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1111\/dom.16239","article-title":"Use of sodium\u2010glucose cotransporter\u20102 inhibitors and risk of dementia: A population\u2010based cohort study","volume":"27","author":"Zhuo","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"23","key":"10.1016\/j.diabres.2025.112197_b0100","doi-asserted-by":"crossref","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective Effect of SGLT2 Inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.diabres.2025.112197_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.diabres.2025.112197_b0110","article-title":"Anti\u2010inflammatory effects of empagliflozin and gemigliptin on LPS\u2010stimulated macrophage via the IKK\/NF\u2010\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J Immunol Res"},{"key":"10.1016\/j.diabres.2025.112197_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-018-0695-y","article-title":"Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy","volume":"17","author":"Irace","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.diabres.2025.112197_b0120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/brainsci9030057","article-title":"Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db\/db mouse","volume":"9","author":"Hayden","year":"2019","journal-title":"Brain Sci"},{"issue":"3","key":"10.1016\/j.diabres.2025.112197_b0125","first-page":"447","article-title":"Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer\u2019s disease-diabetes type 2 linkage via an enzoinformatics study","volume":"13","author":"Rizvi","year":"2014","journal-title":"CNS Neurol Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)"},{"issue":"6","key":"10.1016\/j.diabres.2025.112197_b0130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/neurolint16060124","article-title":"New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia","volume":"16","author":"Hung","year":"2024","journal-title":"Neurol Int"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725002116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725002116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T04:51:11Z","timestamp":1778388671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725002116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"alternative-id":["S0168822725002116"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112197","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A five-year retrospective cohort analysis of 160,752 patients","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112197"}}